Ensifentrine is under clinical development by Verona Pharma and currently in Phase II for Allergic Asthma. According to GlobalData, Phase II drugs for Allergic Asthma have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Ensifentrine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ensifentrine (RPL-554) is under development for the treatment of allergic asthma, mild to moderate chronic asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, cystic fibrosis, non cystic fibrosis bronchiectasis and coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The drug candidate is administered through inhalation route as a suspension. RPL-554 acts by targeting both phosphodiesterase 3 and phosphodiesterase 4 enzymes. It was also under development for the treatment of allergic rhinitis.
Verona Pharma overview
Verona Pharma is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company’s lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials. Additionally the company is evaluating ensifentrine for the treatment of cystic fibrosis and asthma under its Phase II trials. Verona Pharma is headquartered in London, the UK.
For a complete picture of Ensifentrine’s drug-specific PTSR and LoA scores, buy the report here.